Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673567 · ClinicalTrials.gov registry record · Phase 1
To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02673567 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 64 participants.
The verdict
NCT02673567, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a single center, randomized, double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of subcutaneous administration of TEV-48125 (single ascending doses and single doses up to 900 mg) in Japanese and Caucasian healthy subjects.
Interventions
- DRUG Placebo
- DRUG TEV-48125 - 1
- DRUG TEV-48125 - 2
- DRUG TEV-48125 - 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2017-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02673567
The ClinicalTrials.gov registry entry for NCT02673567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02673567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02673567 about?
NCT02673567 is a clinical study titled "To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125". This is a single center, randomized, double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of subcutaneous administration of TEV-48125 (single ascending doses and single doses up to 900 mg) in Japanese and Caucasian healthy subjects.
What is the current status of trial NCT02673567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2016-03-31. Estimated completion is 2017-02-10.
What interventions are being tested in trial NCT02673567?
The interventions under investigation include: Placebo (DRUG), TEV-48125 - 1 (DRUG), TEV-48125 - 2 (DRUG), TEV-48125 - 3 (DRUG).
Who is sponsoring clinical trial NCT02673567?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.